Literature DB >> 21081113

Pancreatic stellate cells promote epithelial-mesenchymal transition in pancreatic cancer cells.

Kazuhiro Kikuta1, Atsushi Masamune, Takashi Watanabe, Hiroyuki Ariga, Hiromichi Itoh, Shin Hamada, Kennichi Satoh, Shinichi Egawa, Michiaki Unno, Tooru Shimosegawa.   

Abstract

The interaction between pancreatic cancer cells and pancreatic stellate cells (PSCs), a major profibrogenic cell type in the pancreas, is receiving increasing attention. There is accumulating evidence that PSCs promote the progression of pancreatic cancer by increasing cancer cell proliferation and invasion as well as by protecting them from radiation- and gemcitabine-induced apoptosis. Because epithelial-mesenchymal transition (EMT) plays a critical role in the progression of pancreatic cancer, we hypothesized that PSCs promote EMT in pancreatic cancer cells. Panc-1 and SUIT-2 pancreatic cancer cells were indirectly co-cultured with human PSCs isolated from patients undergoing operation for pancreatic cancer. The expression of epithelial and mesenchymal markers was examined by real-time PCR and immunofluorescent staining. The migration of pancreatic cancer cells was examined by scratch and two-chamber assays. Pancreatic cancer cells co-cultured with PSCs showed loose cell contacts and a scattered, fibroblast-like appearance. The expression of E-cadherin, cytokeratin 19, and membrane-associated β-catenin was decreased, whereas vimentin and Snail (Snai-1) expression was increased more in cancer cells co-cultured with PSCs than in mono-cultured cells. The migration of pancreatic cancer cells was increased by co-culture with PSCs. The PSC-induced decrease of E-cadherin expression was not altered by treatment with anti-TGF-β-neutralizing antibody, excluding a central role of TGF-β in this process. In conclusion, PSCs promoted EMT in pancreatic cancer cells suggesting a novel mechanism by which PSCs contribute to the aggressive behavior of pancreatic cancer cells.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21081113     DOI: 10.1016/j.bbrc.2010.11.040

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  85 in total

Review 1.  Altered gene products involved in the malignant reprogramming of cancer stem/progenitor cells and multitargeted therapies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Mol Aspects Med       Date:  2013-08-29

2.  Apoptosis and anergy of T cell induced by pancreatic stellate cells-derived galectin-1 in pancreatic cancer.

Authors:  Dong Tang; Jun Gao; Sen Wang; Zhongxu Yuan; Nianyuan Ye; Yang Chong; Chuanqi Xu; Xuetong Jiang; Bin Li; Wei Yin; Yi Miao; Daorong Wang; Kuirong Jiang
Journal:  Tumour Biol       Date:  2015-03-01

3.  JDP2 inhibits the epithelial-to-mesenchymal transition in pancreatic cancer BxPC3 cells.

Authors:  Zhe Liu; Ruixia Du; Jin Long; Anbing Dong; Jianpeng Fan; Kejian Guo; Yuanhong Xu
Journal:  Tumour Biol       Date:  2012-04-27

4.  Cyclopamine-loaded core-cross-linked polymeric micelles enhance radiation response in pancreatic cancer and pancreatic stellate cells.

Authors:  Jun Zhao; Chunhui Wu; James Abbruzzese; Rosa F Hwang; Chun Li
Journal:  Mol Pharm       Date:  2015-05-12       Impact factor: 4.939

5.  CCR9-mediated signaling through β-catenin and identification of a novel CCR9 antagonist.

Authors:  Sangjun Lee; Eileen L Heinrich; Lily Li; Jianming Lu; Audrey H Choi; Rachel A Levy; Jeffrey E Wagner; M L Richard Yip; Nagarajan Vaidehi; Joseph Kim
Journal:  Mol Oncol       Date:  2015-05-12       Impact factor: 6.603

Review 6.  Human correlates of provocative questions in pancreatic pathology.

Authors:  Oliver G McDonald; Anirban Maitra; Ralph H Hruban
Journal:  Adv Anat Pathol       Date:  2012-11       Impact factor: 3.875

Review 7.  Targeting the cancer-stroma interaction: a potential approach for pancreatic cancer treatment.

Authors:  Xuqi Li; Qingyong Ma; Qinhong Xu; Wanxing Duan; Jianjun Lei; Erxi Wu
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

8.  Lipocalin-2 is associated with a good prognosis and reversing epithelial-to-mesenchymal transition in pancreatic cancer.

Authors:  Bin Xu; Da-Yong Jin; Wen-Hui Lou; Dan-Song Wang
Journal:  World J Surg       Date:  2013-08       Impact factor: 3.352

Review 9.  Inflammation and pancreatic cancer: disease promoter and new therapeutic target.

Authors:  Shin Hamada; Atsushi Masamune; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2013-11-30       Impact factor: 7.527

Review 10.  Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells.

Authors:  Michael Friberg Bruun Nielsen; Michael Bau Mortensen; Sönke Detlefsen
Journal:  World J Gastroenterol       Date:  2016-03-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.